Immunovant Provides Development Updates and Reports Financial Results for the Quarter Ended September 30, 2024GlobeNewsWire • 11/07/24
Immunovant Announces Oral Presentation of Late Breaking Abstract for Phase 2 Graves' Disease Clinical Data at the 2024 American Thyroid Association (ATA) Annual MeetingGlobeNewsWire • 10/29/24
IMVT Stock Up on Upbeat Data From Graves' Disease Study of BatoclimabZacks Investment Research • 09/09/24
Long Assets On Path To Creating Significant Value, Shorting Remains Very ChallengingSeeking Alpha • 08/06/24
Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024GlobeNewsWire • 05/29/24
Wall Street Analysts Think Immunovant (IMVT) Could Surge 68.63%: Read This Before Placing a BetZacks Investment Research • 05/13/24
Wall Street's Favorite Biotech Stocks? 3 Names That Could Make You Filthy RichInvestorPlace • 03/25/24
Argenx, Immunovant Soar — As Tourmaline Plummets — On A Rival's Lackluster Test ResultsInvestors Business Daily • 03/21/24
Why Is Immunovant, Inc. (IMVT) Down 14.7% Since Last Earnings Report?Zacks Investment Research • 03/13/24
Here's Why Immunovant, Inc. (IMVT) is Poised for a Turnaround After Losing -8.02% in 4 WeeksZacks Investment Research • 03/08/24
Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended December 31, 2023GlobeNewsWire • 02/12/24